IRIS Accounts Production v25.1.3.33 09550055 Board of Directors 1.5.24 30.4.25 30.4.25 0 0 false true false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh095500552024-04-30095500552025-04-30095500552024-05-012025-04-30095500552023-04-30095500552023-05-012024-04-30095500552024-04-3009550055ns15:EnglandWales2024-05-012025-04-3009550055ns14:PoundSterling2024-05-012025-04-3009550055ns10:Director12024-05-012025-04-3009550055ns10:PrivateLimitedCompanyLtd2024-05-012025-04-3009550055ns10:SmallEntities2024-05-012025-04-3009550055ns10:AuditExempt-NoAccountantsReport2024-05-012025-04-3009550055ns10:SmallCompaniesRegimeForDirectorsReport2024-05-012025-04-3009550055ns10:SmallCompaniesRegimeForAccounts2024-05-012025-04-3009550055ns10:FullAccounts2024-05-012025-04-3009550055ns5:CurrentFinancialInstruments2025-04-3009550055ns5:CurrentFinancialInstruments2024-04-3009550055ns5:ShareCapital2025-04-3009550055ns5:ShareCapital2024-04-3009550055ns5:RetainedEarningsAccumulatedLosses2025-04-3009550055ns5:RetainedEarningsAccumulatedLosses2024-04-3009550055ns10:RegisteredOffice2024-05-012025-04-3009550055ns5:WithinOneYearns5:CurrentFinancialInstruments2025-04-3009550055ns5:WithinOneYearns5:CurrentFinancialInstruments2024-04-300955005512024-05-012025-04-30
REGISTERED NUMBER: 09550055 (England and Wales)















UNAUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 APRIL 2025

FOR

NEXUS MEDICAL (UK) LIMITED

NEXUS MEDICAL (UK) LIMITED (REGISTERED NUMBER: 09550055)

CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2025










Page

Statement of Financial Position 1

Notes to the Financial Statements 2 to 4


NEXUS MEDICAL (UK) LIMITED (REGISTERED NUMBER: 09550055)

STATEMENT OF FINANCIAL POSITION
30 APRIL 2025

30.4.25 30.4.24
Notes £    £   
CURRENT ASSETS
Debtors 4 - 1,957
Cash at bank 218 539
218 2,496
CREDITORS
Amounts falling due within one year 5 (3,908 ) (2,996 )
NET CURRENT LIABILITIES (3,690 ) (500 )
TOTAL ASSETS LESS CURRENT
LIABILITIES

(3,690

)

(500

)

CAPITAL AND RESERVES
Called up share capital 100 100
Retained earnings (3,790 ) (600 )
(3,690 ) (500 )

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 30 April 2025.

The members have not required the company to obtain an audit of its financial statements for the year ended 30 April 2025 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Statement of Income and Retained Earnings has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 30 June 2025 and were signed on its behalf by:





M A Barnes - Director


NEXUS MEDICAL (UK) LIMITED (REGISTERED NUMBER: 09550055)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2025


1. STATUTORY INFORMATION

NEXUS MEDICAL (UK) LIMITED is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address are as below:

Registered number: 09550055

Registered office: Priory House
Llawhaden
Narberth
Pembrokeshire
SA67 8HS

2. ACCOUNTING POLICIES

BASIS OF PREPARING THE FINANCIAL STATEMENTS
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

The financial statements are prepared in sterling, which is the functional currency of the entity.

GOING CONCERN
The directors have given the company assurance that they will continue to support future trading of the company. Accordingly, the directors consider it appropriate to prepare the financial statements on the going concern basis.

REVENUE RECOGNITION
Turnover is measured at the fair value of the consideration received or receivable and represents amounts receivable for services rendered, stated net of discounts and of Value Added Tax.

NEXUS MEDICAL (UK) LIMITED (REGISTERED NUMBER: 09550055)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 30 APRIL 2025


2. ACCOUNTING POLICIES - continued

FINANCIAL INSTRUMENTS
A financial asset or a financial liability is recognised only when the entity becomes a party to the contractual provisions of the instrument.

Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

Debt instruments are subsequently measured at amortised cost.

Financial assets that are measured at cost or amortised cost are reviewed for objective evidence of impairment at the end of each reporting date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss immediately.

For all equity instruments regardless of significance, and other financial assets that are individually significant, these are assessed individually for impairment. Other financial assets are either assessed individually or grouped on the basis of similar credit risk characteristics.

Any reversals of impairment are recognised in profit or loss immediately, to the extent that the reversal does not result in a carrying amount of the financial asset that exceeds what the carrying amount would have been had the impairment not previously been recognised.

Where the contractual obligations of financial instruments (including share capital) are equivalent to a similar debt instrument, those financial instruments are classed as financial liabilities. Financial liabilities are presented as such in the balance sheet. Finance costs and gains or losses relating to financial liabilities are included in the profit and loss account. Finance costs are calculated so as to produce a constant rate of return on the outstanding liability.

Where the contractual terms of share capital do not have any terms meeting the definition of a financial liability then this is classed as an equity instrument. Dividends and distributions relating to equity instruments are debited direct to equity.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was NIL (2024 - NIL).

4. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
30.4.25 30.4.24
£    £   
Other debtors - 50
Directors' loan accounts - 1,907
- 1,957

5. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
30.4.25 30.4.24
£    £   
Tax 1,348 2,096
Directors' loan accounts 761 -
Accruals and deferred income 1,799 900
3,908 2,996

NEXUS MEDICAL (UK) LIMITED (REGISTERED NUMBER: 09550055)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 30 APRIL 2025


6. EVENTS AFTER THE END OF THE REPORTING PERIOD

There were no significant events up to the date of approval of the financial statements by the Board.

7. GOING CONCERN

The directors have given the company assurance that they will continue to support future trading of the company. Accordingly, the directors consider it appropriate to prepare the financial statements on the going concern basis.